Corcept Therapeutics (CORT) Q1 2026 earnings review
Lifyorli Launch Spurs Guidance Hike, But Crushes Q1 Profitability
Corcept delivered a highly transitional quarter. The early FDA approval of Lifyorli for ovarian cancer is a massive strategic win that prompted a full-year guidance increase. However, the costs of this launch and lingering pharmacy bottlenecks dragged the company into unprofitability. Revenue of $164.9M grew just 5% YoY and collapsed 18% sequentially from Q4. Net income reversed to a $31.8M loss, crushed by a 60% YoY surge in SG&A expenses. Management points to a completed pharmacy transition in February and record patient starts in March/April as proof the worst is over. The evolution into a multi-franchise company is officially underway, but near-term margins have taken a severe beating.
🐂 Bull Case
FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer more than three months ahead of its PDUFA date. It was rapidly added to NCCN Guidelines as a preferred regimen, and management reports 'vigorous' early uptake.
The Cushing's business completed its transition to a new specialty pharmacy vendor in February. Unblocking this supply chain constraint led to all-time highs in patient starts during March and April, underpinning the guidance raise.
🐻 Bear Case
Net income flipped violently from +$23.9M in Q4 to a -$31.8M loss in Q1. SG&A expenses skyrocketed 60% YoY to support the new launch, completely destroying operating margins in the near term.
Despite a growing market narrative, Q1 top-line dropped 18% QoQ ($164.9M vs $202.1M in Q4), highlighting the severity of the operational disruptions experienced before the February pharmacy transition was finalized.
⚖️ Verdict: ⚪
Neutral. The long-term thesis is significantly de-risked by Lifyorli's approval, but the short-term financial picture is messy. The massive sequential revenue drop and operating margin collapse require management to execute flawlessly in Q2 to restore profitability as promised.
Key Themes
Oncology Launch Transforms the Company
The FDA approval of Lifyorli in March fundamentally shifts Corcept away from sole reliance on Korlym. The rapid addition to the NCCN Guidelines as a preferred regimen gives it immediate commercial traction. This milestone validates the oncology pipeline and sets the stage for broader solid tumor applications, turning Corcept into a multi-franchise commercial operation.
SG&A Explosion Destroys Margins
Operating expenses surged to $214.5M (up 39% YoY), heavily driven by a 60% YoY explosion in SG&A to $145.4M. Management attributed this to launch preparations for Lifyorli and growth initiatives in the Cushing's business. This aggressive spending caused operating margins to violently reverse. While management expects a return to profitability in Q2, the new baseline for commercial spend will likely keep margins depressed compared to historical norms.
Regulatory Cloud Over Cushing's Franchise
Despite the oncology win, the core Cushing's business remains vulnerable. Following the FDA's Complete Response Letter (CRL) for the relacorilant Cushing's NDA last quarter, management remains 'engaged with the FDA to determine the best path forward.' With Korlym facing ongoing generic patent litigation threats, the delay in upgrading the endocrinology franchise to relacorilant is a material risk.
Pharmacy Transition Finally Complete
The specialty pharmacy vendor bottlenecks that severely constrained revenue growth in late 2025 and Q1 2026 have finally been resolved. Management confirmed the transition to a new vendor finished in February. This unblocking led to all-time highs in patient starts during March and April, which gave management the confidence to hike full-year revenue guidance.
Broadening Cortisol Modulation Pipeline
Clinical catalysts are stacking up for late 2026. Key upcoming readouts include the BELLA trial for ovarian cancer combinations and the MONARCH Phase 2b trial for MASH by year-end. Furthermore, a Phase 3 trial for dazucorilant in ALS is slated to begin later this year, aiming to replicate the dramatic survival benefits seen in the Phase 2 DAZALS study.
Other KPIs
Stable. Down slightly from $532.4M at year-end 2025. This provides a strong balance sheet to absorb the Q1 cash burn and fund the Lifyorli launch without any immediate dilution risk.
Stable. Up 9% YoY. A relatively controlled investment compared to the SG&A explosion, supporting a vast array of mid-to-late stage trials across oncology, ALS, and MASH.
Guidance
Accelerating. Management raised both the bottom and top ends by $50M from the prior range. The midpoint of $1.0B implies ~31% YoY growth over FY25's $761.4M. This indicates immense confidence in the Lifyorli launch and the newly unbottlenecked Korlym distribution network.
Reversing. After posting a $31.8M loss in Q1, management explicitly promised a return to profitability in Q2. This implies that either Q1's SG&A spike contained significant one-time launch costs, or that the Q2 revenue acceleration from Lifyorli will rapidly outpace the new expense run rate.
Key Questions
SG&A Structural Run Rate
What portion of the $145.4M SG&A expense in Q1 was one-time launch preparation for Lifyorli versus the new structural run-rate required to support two separate commercial franchises?
Cushing's NDA Resubmission Path
Regarding the Cushing's NDA for relacorilant, what specific paths are being discussed with the FDA following the CRL, and is there a scenario where a new clinical trial is required?
Authorized Generic Pricing Impact
How is the increasing mix shift toward the authorized generic for Korlym impacting gross-to-net pricing now that the pharmacy transition is complete and volume is flowing normally?